Mallinckrodt PLC

Latest Mallinckrodt PLC News and Updates

  • uploads///MNK
    Fund Managers

    Adage Capital adds a new position in Mallinckrodt

    Adage Capital added a new position in Mallinckrodt Plc (MNK) in the third quarter of 2014. The position accounted for 0.82% of the fund’s total portfolio.

    By Samantha Nielson
  • uploads///holdings in valeant
    Company & Industry Overviews

    What Does Valeant’s Institutional Ownership Look Like?

    Of its total outstanding shares, Valeant Pharmaceuticals’ (VRX) institutional ownership stood at 69.2%.

    By Jillian Dabney
  • uploads///MArket opportunity for Acthar
    Company & Industry Overviews

    Inside Mallinckrodt’s Major Valuation Catalysts

    Acthar is Mallinckrodt’s (MNK) leading product, and the company plans to achieve mid-single-digit to low-double-digit growth for the drug in fiscal 2016.

    By Jillian Dabney
  • uploads///US Quarterly Economic Growth
    Macroeconomic Analysis

    The US Economy: Fischer and Brainard Weigh In

    Stanley Fischer expressed his views on the US economy at the G30 Annual International Banking Seminar on October 11. This came three days after the dovish minutes of the FOMC September meeting.

    By David Ashworth
  • uploads///segemnts and margins
    Company & Industry Overviews

    Yes, There Will Be Margin Erosion for Valeant in 2017

    Of its three businesses, Bausch & Lomb’s share in Valeant Pharmaceuticals’ (VRX) overall EBITA (earnings before interest, tax, and amortization) was 32%.

    By Jillian Dabney
  • uploads///pulse trace _
    Company & Industry Overviews

    Analyst Ratings for Endo International and Peers in August

    In the second quarter, Endo International (ENDP) reported revenues of $715 million, which is a YoY decline of 18.4%.

    By Margaret Patrick
  • uploads///revenue ee
    Earnings Report

    How Did Valeant Fare in 2Q16?

    Valeant Pharmaceuticals (VRX) announced earnings for 2Q16 on August 9, 2016.

    By Jillian Dabney
  • uploads///ANR
    Company & Industry Overviews

    What Do Analysts Recommend for Valeant after Recent Happenings

    The consensus 12-month target price for Valeant Pharmaceuticals is $36, which translates to a ~77.3% return potential compared to Valeant’s closing price of $20.3 on November 2, 2016.

    By Jillian Dabney
  • uploads///generics
    Earnings Report

    Inside the Double-Digit Fall for Mallinckrodt’s Specialty Generics Business in 2016

    Specialty Generics’ contribution to Mallinckrodt’s net sales fell by 18% to $1 billion in 2016. The business had a 31% share in total net sales in 2016.

    By Jillian Dabney
  • uploads///Geographic exposure
    Company & Industry Overviews

    Central Nervous System Is Key to Teva’s Specialty Medicines

    Revenues for Teva’s (TEVA) Specialty Medicines segment grew by 2.1% to $8,560 million in 2014, from $8,388 million in 2013.

    By Nicole Sario
  • uploads///operating segments
    Earnings Report

    A Look at Mallinckrodt’s Operating Segments

    Mallinckrodt (MNK) is a specialty pharmaceuticals company that relies on volume-driven growth. Let’s discuss the performances of its three segments.

    By Jillian Dabney
  • uploads///Adage
    Financials

    A key overview of Adage Capital’s holdings in 3Q14

    Adage Capital’s US long portfolio grew from $38.69 billion in 2Q14 to $40.2 billion in 3Q14. The portfolio comprised around 699 stocks.

    By Samantha Nielson
  • uploads///KMI
    Energy & Utilities

    Kinder Morgan’s position with Adage Capital eliminated

    Adage Capital exited a position in Kinder Morgan Inc (KMI) in the third quarter. The position accounted for 0.37% of the fund’s total 2Q portfolio.

    By Samantha Nielson
  • uploads///C
    Financials

    Citigroup gets raised position with Adage Capital

    Adage Capital raised its position in Citigroup Inc. (C) in the third quarter. The position accounted for 0.98% of the fund’s total 3Q portfolio.

    By Samantha Nielson
  • uploads///NI
    Energy & Utilities

    Adage Capital raises its position in NiSource

    Adage Capital raised its position in NiSource Inc. (NI) in the third quarter. The position accounted for 0.52% of the fund’s total 3Q14 portfolio.

    By Samantha Nielson
  • uploads///human skeleton _
    Company & Industry Overviews

    Analysts’ Views on Endo International and Mallinckrodt

    Most analysts covering Endo International (ENDP) and Mallinckrodt (MNK) recommend “hold.” On March 5, Endo closed at $8.72, and Mallinckrodt closed at $22.39.

    By Margaret Patrick
  • uploads///baxter
    Company & Industry Overviews

    Baxter International Completes Its Mallinckrodt Assets Buy

    Baxter (BAX) announced the completion of its acquisition of Recothrom and Preveleak assets from Mallinckrodt for $185.0 million.

    By Sarah Collins
  • uploads///Chart
    Company & Industry Overviews

    Performance of Incyte’s Jakafi in the United States

    Revenues for Jakafi rose more than 42.0% to $852.8 million in 2016, from $601.0 million in 2015.

    By Mike Benson
  • uploads///operating segments
    Earnings Report

    How Did Mallinckrodt’s Specialty Brands Perform in 2016?

    Specialty Brands had a 69% in Mallinckrodt’s total revenue in 2016, while Specialty Generics had a 31% share.

    By Jillian Dabney
  • uploads///revenue
    Earnings Report

    Mallinckrodt’s Revenue Growth in Fiscal 4Q16

    On an annual basis, MNK’s net sales soared by 16% to $3.4 billion in 2016. Despite its better-than-estimated performance, shares fell by 9% on November 29.

    By Jillian Dabney
  • uploads///Graph
    Company & Industry Overviews

    Valeant Looks to Boost Profit Margins through the Walgreens Deal

    On December 15, 2015, Valeant Pharmaceuticals (VRX) announced its decision to enter into a fulfillment agreement with Walgreens.

    By Margaret Patrick
  • uploads///margins
    Earnings Report

    Can Mallinckrodt Expand Its Margins?

    Wall Street analysts expect Mallinckrodt’s (MNK) net margin to jump to 24.3% in 3Q16 from 10% in 3Q15.

    By Jillian Dabney
  • uploads///ev to ebitda
    Company & Industry Overviews

    The Truth behind Horizon’s EV-to-EBITDA Performance

    On June 29, 2016, Horizon Pharma was trading at a forward EV-to-EBITDA multiple of 4.67x, which is at a discount when compared with peers.

    By Jillian Dabney
  • uploads///Graph
    Company & Industry Overviews

    Inside Neurocrine Biosciences’ Analyst Recommendations in 2016

    Based on the recommendations of eight brokerage firms, a Bloomberg survey reported that 100% of analysts gave Neurocrine Biosciences “buy” recommendations.

    By Margaret Patrick
  • uploads///nitropress and isuprel
    Company & Industry Overviews

    The Facts behind the Valeant Drug Pricing Controversy

    Valeant Pharmaceuticals International (VRX) significantly raised the prices of two of its heart drugs—Nitropress and Isuprel—which caused a controversy and an outrage.

    By Jillian Dabney
  • uploads///global brands
    Company & Industry Overviews

    What Happened in the Valeant-Philidor Controversy?

    Valeant’s (VRX) controversies started with Philidor, a specialty pharmacy company that was accused of altering doctor’s prescriptions so it could sell more of Valeant’s costly drugs.

    By Jillian Dabney
  • uploads///VOD
    Company & Industry Overviews

    Defitelio: Volume and Pricing Challenges

    Jazz Pharmaceuticals’ Defitelio is the first and only approved treatment that increases survival in VOD patients with multi-organ dysfunction (or MOD).

    By Jillian Dabney
  • uploads///Natpara
    Company & Industry Overviews

    Shire’s Acquisition Gives It Natpara and Gattex

    Gattex is the first and only analog of glucagon-like peptide-2 (or GLP-2) indicated for short bowel syndrome. The drug is known as Gattex in the United States and Revestive in Europe.

    By Jillian Dabney
  • uploads///Graph
    Company & Industry Overviews

    Neurocrine Biosciences’ Valbenazine Launch: What You Need to Know

    Neurocrine Biosciences (NBIX) expects to submit a new drug application to the FDA for Valbenazine in 2016.

    By Margaret Patrick
  • uploads///acquisitions
    Company & Industry Overviews

    How Horizon Became a Growth Stock

    Over the past 18 months, Horizon Pharma has acquired three orphan drugs. The acquisition of Hyperion Therapeutics in May 2015 gave it Ravicti and Buphenyl.

    By Jillian Dabney
  • uploads///Chart
    Macroeconomic Analysis

    Healthcare Stock Mallinckrodt Emerged as One of the Top Stocks

    The stocks at the top of the SPDR S&P 500 ETF on December 30, 2015, were Allegheny Technologies (ATI), Mallinckrodt (MNK), and Tesoro Corporation (TSO).

    By Renee Blakely
  • uploads///Tenet Healthcare Corp versus UnitedHealth Group
    Macroeconomic Analysis

    J.M. Smucker Led the SPY ETF with a 7.0% Gain

    J.M. Smucker posted EPS of $1.62, beating the consensus estimate of $1.52. It also reported net sales of ~$2.1 billion, in line with the market expectation.

    By Renee Blakely
  • uploads///Graph Part
    Company & Industry Overviews

    PerkinElmer and Mallinckrodt Help Bottom Ten Stocks in XLV

    PerkinElmer (PKI) with a return of 5.94% was the best performer of XLV’s bottom ten stocks.

    By Peter Neil
  • uploads///Margins
    Earnings Report

    Why Teva’s Generic Medicines Profitability Improved in 1Q15

    Teva’s increased profitability for its generic medicines was partially offset by decreased profitability of its specialty medicines, which were down by 13% in 1Q15 from 1Q14.

    By Nicole Sario
  • uploads///US High Yield Bond Fund Flows
    Company & Industry Overviews

    High-Yield Bond Funds See Inflows Pick Up Pace in April 10 Week

    The largest issuers of high-yield bonds in the primary market last week were Fiat Chrysler Automobiles, GM Financial, and Mallinckrodt International.

    By David Ashworth
  • uploads///Junk Bond Yields in  and
    Company & Industry Overviews

    Fiat Chrysler, GM Financial Issue Largest Bonds in April 10 Week

    Investors showed interest in high-yield bonds in the week ended April 10. Fiat Chrysler issued B2/BB- rated junk bonds worth $3 billion.

    By David Ashworth
  • uploads///US High Yield Bond Market Issuance
    Company & Industry Overviews

    High-Yield Debt Issuance Gathers Steam in Week to April 10

    In the week to April 10, junk bonds, or high-yield debt issuers, returned to the primary market. It was the same week the FOMC released its March 2015 meeting minutes.

    By David Ashworth
  • uploads///First to files
    Company & Industry Overviews

    Actavis Focuses on Complex Generics and Para IV Filings

    In January 2015, Actavis launched a generic specialty injectable portfolio, containing ~20 products across its therapeutic segments in the US.

    By Nicole Sario
  • uploads///DUK
    Fund Managers

    Adage Capital adds stake in Duke Energy

    Adage Capital added a new position in Duke Energy in the third quarter. The position accounted for 0.20% of the fund’s total 3Q portfolio.

    By Samantha Nielson
  • uploads///TRW
    Fund Managers

    TRW Automotive Holdings is Adage Capital’s new position

    Adage Capital added a new position in TRW Automotive Holdings, which accounted for 0.32% of the fund’s total 3Q14 portfolio.

    By Samantha Nielson
  • © Copyright 2022 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.